Optimizing immune cells for glioblastoma treatment
Part of Cancer clinical trials.
This trial tests a new approach using immune cells called cytokine-induced killer cells to treat glioblastoma. It aims to find the best way to prepare these cells to fight the tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer).
- You must be willing and able to give informed consent.
- You cannot be pregnant.
- You cannot have an active infection or certain blood abnormalities.
- You cannot have a weakened immune system or certain autoimmune diseases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding a personalized vaccine made from your own immune cells and tumor can help standard chemotherapy and radiation work better against glioblastoma. It is for patients who have already had surgery and are starting or have just finished their first round of chemoradiation.
This trial tests a personalized immune therapy made from your own cells (dendritic cells) that target a protein called survivin in glioblastoma. It's given after standard radiation and chemotherapy, and may help your immune system fight the cancer.
This study tests a type of immune-cell therapy (cytokine-induced killer cells) for people with certain grade 1–2 aggressive brain tumors that have already been treated with radiation and temozolomide. It aims to see whether the treatment can control the tumor and be tolerated safely.
This trial tests a type of immune cell treatment (called cytokine-induced killer cells) for advanced, grade 4 malignant glioma that has come back after prior therapy. It aims to slow or control the tumor by using your immune system after temozolomide treatment.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
This trial tests a personalized immune cell treatment for a glioblastoma brain tumor that has a specific marker called EGFRvIII. The cells are made in a lab and given by infusion, and the study aims to see if they can safely target and attack the tumor.
Hear when a new Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.